Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Phase 2 Findings Support Further Development of 5-HT1A Receptor Agonist NLX-112 in Parkinson Disease
April 25th 2025NLX-112 demonstrated safety and potential efficacy in reducing levodopa-induced dyskinesia and improving motor symptoms in Parkinson disease, with additional benefits seen in patients also receiving stable amantadine.
GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose
April 24th 2025Roche has updated its phase 2 GENERATION HD2 trial to continue testing only the higher 100 mg dose of tominersen, following interim data favoring its potential clinical benefit in Huntington disease.
Breaking Down Oculopharyngeal Muscular Dystrophy: From Clinical Gaps to Genetic Gains
April 22nd 2025Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio, offered a clinical and translational overview of OPMD, highlighting current care challenges and the early promise of dual-action gene therapy strategies.
How Personalized Repetitive Transcranial Magnetic Stimulation May Transform Alzheimer Treatment
April 20th 2025Ken Mariash, chief executive officer at Sinaptica, provided commentary on new data from the company’s SinaptiStim neuromodulation system, highlighting its clinical promise in slowing Alzheimer disease progression through targeted, non-drug brain network stimulation.
Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy
April 17th 2025The chief scientific officer at Avidity Biosciences details the mechanism, early results, and future plans for Del-zota, an investigational therapy targeting exon 44 in Duchenne muscular dystrophy.
Afterimage Duration Significantly Longer in Migraine With Aura Than Without
April 16th 2025Afterimage duration was more prolonged in patients with migraine with aura than those without, suggesting differing underlying pathophysiology between the two subtypes despite the exact mechanisms remaining unclear.
FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine
April 15th 2025CT-132, an approach that aims to reduce brain hypersensitivity, becomes the first marketed digital treatment to prevent migraine, intended to be used with other previously approved medications.
Investigational Telitacicept Significantly Improves Myasthenia Gravis Outcomes in Phase 3 Study
April 15th 2025In a late-stage trial, telitacicept demonstrated significant and rapid clinical improvements in gMG, achieving notable symptom reductions, improved quality of life, and strong safety outcomes.